VIIV HEALTHCARE PTY LTD

Halozyme announces FDA approval for Tecentriq Hybreza™, a subcutaneous anti-PD-(L)1 immunotherapy using ENHANZE® technology, reducing injection time to 7 minutes from 30-60 minutes for IV infusion, available for adult indications of IV Tecentriq®.

A single HIV viral load test may yield false positives for those on long-acting injectable cabotegravir (CAB-LA) PrEP, according to a multi-country study. A second test with a new blood sample reliably distinguishes true from false positives. Presented at the 2024 International AIDS Conference, the study highlights the need for optimizing HIV testing methods for CAB-LA PrEP users.

Long-acting injectable cabotegravir (CAB-LA) was safe and well tolerated as HIV pre-exposure prophylaxis (PrEP) before and during pregnancy in a global study among cisgender women, with findings to be presented at the 2024 International AIDS Conference.